Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocbrutinib in Relapsing-Remitting Multiple Sclerosis
NCT07776743Phase 2Recruiting
- Sponsor
- Lupeng Pharmaceutical
- Start
- Aug 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of rocbrutinib in relapsing-remitting multiple sclerosis (RRMS), sponsored by Lupeng Pharmaceutical. Started Aug 2026; status: recruiting.
02
Drugs
rocbrutinib
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT07776743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07776743.